CSBR Champions Oncology (CSBR) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0000771856
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
9
13F, latest reported quarter
Conversions, 180 days
1
Codes C/M, not in net · $111.7K priced
Champions Oncology insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for CHAMPIONS ONCOLOGY, INC. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 24 earlier Form 4 trades (code P or S) here by this insider (24 buys), the last on Jan 11, 2024.
- -11.2% median (-9.2% mean) 90-day return after 24 previous buys.
- The trade is 0.5% of the 198,625 shares held after it.
- No other insider bought within 30 days.
- 9 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Mendelson Daniel Newman bought about $6.5K of CSBR on Jan 12, 2024; 9 funds added in the latest 13F quarter.Context
- 23 earlier Form 4 trades (code P or S) here by this insider (23 buys), the last on Jan 10, 2024.
- -11.1% median (-8.7% mean) 90-day return after 23 previous buys.
- The trade is 1.0% of the 197,625 shares held after it.
- No other insider bought within 30 days.
- 9 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Mendelson Daniel Newman bought about $12.5K of CSBR on Jan 11, 2024; 9 funds added in the latest 13F quarter.Context
- 22 earlier Form 4 trades (code P or S) here by this insider (22 buys), the last on Jan 9, 2024.
- -10.1% median (-8.2% mean) 90-day return after 22 previous buys.
- The trade is 1.5% of the 195,625 shares held after it.
- No other insider bought within 30 days.
- 9 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Mendelson Daniel Newman bought about $18.6K of CSBR on Jan 10, 2024; 9 funds added in the latest 13F quarter.Context
- 21 earlier Form 4 trades (code P or S) here by this insider (21 buys), the last on Jan 8, 2024.
- -9.1% median (-7.6% mean) 90-day return after 21 previous buys.
- The trade is 1.6% of the 192,681 shares held after it.
- No other insider bought within 30 days.
- 9 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Mendelson Daniel Newman bought about $18.8K of CSBR on Jan 9, 2024; 9 funds added in the latest 13F quarter.Context
- 20 earlier Form 4 trades (code P or S) here by this insider (20 buys), the last on Jan 5, 2024.
- -8.6% median (-7.1% mean) 90-day return after 20 previous buys.
- The trade is 0.5% of the 189,681 shares held after it.
- No other insider bought within 30 days.
- 9 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Mendelson Daniel Newman bought about $6.2K of CSBR on Jan 8, 2024; 9 funds added in the latest 13F quarter.26 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
9 funds bought in last quarter
below 86% of Pharma & Biotech
Revenue
+4.4% year over year
more than 52% of Pharma & Biotech
Margin
-2.0% net margin
more than 72% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
1.2% of the float short (float per yahoo 2026-10-26) · 4.4 days to cover · settled 2026-09-30
below 79% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch CSBR
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-28.0%12M
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns CSBR: institutional holders (13F)
13F holdings, latest reported quarter
2,421,673 sh
$14.9M
1,713,720 sh
$10.6M
301,353 sh
$1.9M
295,658 sh
$1.8M
235,400 sh
$1.5M
Congress trades in CSBR
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
CSBR planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
CSBR mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
iShares Micro-Cap ETF
$175.3K position · as of 2026-06-30
0.0%
Small Cap Core Fund
$27.5K position · as of 2026-06-30
0.0%
1290 VT Micro Cap Portfolio
$12.5K position · as of 2026-06-30
0.0%
Fidelity Extended Market Index Fund
$188.4K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$386.7K position · as of 2026-06-30
0.0%
Fidelity Nasdaq Composite Index Fund
$64.1K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return · Ronnie Morris
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2022
$600.0K
$600.0K
$294.3K
n/a
n/a
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. This filer reported no return figures.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 9 funds added last quarter. Each figure is a federal filing, dated the day it went public.
CSBR financials
Revenue growth
+4.4%
XBRL, annual
Net margin
-2.0%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$60.7M
four quarters, 2025-08-01 to 2026-07-31
Revenue, TTM CSBR
| FY Apr 2026 | $59.4M |
| FY Apr 2025 | $56.9M |
| FY Apr 2024 | $50.2M |
| FY Apr 2023 | $53.9M |
| FY Apr 2022 | $49.1M |
| Jul 2026 | $15.2M |
| Apr 2026 | $13.8M |
| Jan 2026 | $16.6M |
| Oct 2025 | $15.0M |
| Jul 2025 | $14.0M |
| Apr 2025 | $12.4M |
| Jan 2025 | $17.0M |
| Oct 2024 | $13.5M |
At each fiscal year end
Single quarter
Net margin, TTM
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Net margin, TTM CSBR
| FY Apr 2026 | n/a |
| FY Apr 2025 | +0.0% |
| FY Apr 2024 | -0.0% |
| FY Apr 2023 | -9.9% |
| FY Apr 2022 | +1.1% |
| Jul 2026 | -2.8% |
| Apr 2026 | +3.7% |
| Jan 2026 | -1.7% |
| Oct 2025 | +1.8% |
| Jul 2025 | -3.3% |
| Apr 2025 | -52.9% |
| Jan 2025 | +26.4% |
| Oct 2024 | +5.4% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$6.1M
operating cash flow minus capex, 2025-08-01 to 2026-07-31
Free cash flow, TTM CSBR
| FY Apr 2026 | -$5.0M |
| FY Apr 2025 | $7.0M |
| FY Apr 2024 | -$7.0M |
| FY Apr 2023 | $1.1M |
| FY Apr 2022 | $4.1M |
| Jul 2026 | -$547.0K |
| Apr 2026 | -$2.2M |
| Jan 2026 | -$1.4M |
| Oct 2025 | -$2.0M |
| Jul 2025 | $554.0K |
| Apr 2025 | $6.6M |
| Jan 2025 | $448.0K |
| Oct 2024 | -$377.0K |
At each fiscal year end
Single quarter
Debt to equity
n/a
no debt line filed
Debt to equity CSBR
| FY Apr 2026 | n/a |
| FY Apr 2025 | n/a |
| FY Apr 2024 | n/a |
| FY Apr 2023 | n/a |
| FY Apr 2022 | n/a |
| Jul 2026 | n/a |
| Apr 2026 | n/a |
| Jan 2026 | n/a |
| Oct 2025 | n/a |
| Jul 2025 | n/a |
| Apr 2025 | n/a |
| Jan 2025 | n/a |
| Oct 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt line filed
Cash flow to debt CSBR
| FY Apr 2026 | n/a |
| FY Apr 2025 | n/a |
| FY Apr 2024 | n/a |
| FY Apr 2023 | n/a |
| FY Apr 2022 | n/a |
| Jul 2026 | n/a |
| Apr 2026 | n/a |
| Jan 2026 | n/a |
| Oct 2025 | n/a |
| Jul 2025 | n/a |
| Apr 2025 | n/a |
| Jan 2025 | n/a |
| Oct 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Return on equity CSBR
| FY Apr 2026 | n/a |
| FY Apr 2025 | +0.5% |
| FY Apr 2024 | -0.5% |
| FY Apr 2023 | -77.7% |
| FY Apr 2022 | +6.6% |
| Jul 2026 | n/a |
| Apr 2026 | n/a |
| Jan 2026 | -143.7% |
| Oct 2025 | -92.1% |
| Jul 2025 | -111.7% |
| Apr 2025 | +0.5% |
| Jan 2025 | +803.0% |
| Oct 2024 | +1,724% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Return on assets CSBR
| FY Apr 2026 | n/a |
| FY Apr 2025 | +0.0% |
| FY Apr 2024 | -0.0% |
| FY Apr 2023 | -15.3% |
| FY Apr 2022 | +1.7% |
| Jul 2026 | n/a |
| Apr 2026 | n/a |
| Jan 2026 | -23.7% |
| Oct 2025 | -8.1% |
| Jul 2025 | -6.4% |
| Apr 2025 | +0.0% |
| Jan 2025 | +47.7% |
| Oct 2024 | +24.9% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital CSBR
| FY Apr 2026 | n/a |
| FY Apr 2025 | n/a |
| FY Apr 2024 | n/a |
| FY Apr 2023 | n/a |
| FY Apr 2022 | n/a |
| Jul 2026 | n/a |
| Apr 2026 | n/a |
| Jan 2026 | n/a |
| Oct 2025 | n/a |
| Jul 2025 | n/a |
| Apr 2025 | n/a |
| Jan 2025 | n/a |
| Oct 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-9.1%
operating income (EBIT proxy) over average of 2025-07-31 and 2026-07-31 minus current liabilities
Return on capital employed CSBR
| FY Apr 2026 | -14.7% |
| FY Apr 2025 | +69.6% |
| FY Apr 2024 | -85.7% |
| FY Apr 2023 | -34.5% |
| FY Apr 2022 | +3.5% |
| Jul 2026 | -9.1% |
| Apr 2026 | -14.7% |
| Jan 2026 | -28.3% |
| Oct 2025 | +29.9% |
| Jul 2025 | +39.6% |
| Apr 2025 | +69.6% |
| Jan 2025 | +80.8% |
| Oct 2024 | -11.5% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing CSBR
| FY Apr 2026 | n/a |
| FY Apr 2025 | 22.34x |
| FY Apr 2024 | n/a |
| FY Apr 2023 | n/a |
| FY Apr 2022 | 192.00x |
| Jul 2026 | n/a |
| Apr 2026 | n/a |
| Jan 2026 | n/a |
| Oct 2025 | 40.24x |
| Jul 2025 | 31.60x |
| Apr 2025 | 22.34x |
| Jan 2025 | 24.98x |
| Oct 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no debt line filed
Enterprise value CSBR
| FY Apr 2026 | n/a |
| FY Apr 2025 | n/a |
| FY Apr 2024 | n/a |
| FY Apr 2023 | n/a |
| FY Apr 2022 | n/a |
| Jul 2026 | n/a |
| Apr 2026 | n/a |
| Jan 2026 | n/a |
| Oct 2025 | n/a |
| Jul 2025 | n/a |
| Apr 2025 | n/a |
| Jan 2025 | n/a |
| Oct 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-9.1%
TTM free cash flow over market value at close 2026-10-26
FCF yield CSBR
| FY Apr 2026 | -6.1% |
| FY Apr 2025 | +7.1% |
| FY Apr 2024 | -10.6% |
| FY Apr 2023 | +1.6% |
| FY Apr 2022 | +4.0% |
| Jul 2026 | -8.2% |
| Apr 2026 | -6.1% |
| Jan 2026 | +3.8% |
| Oct 2025 | +6.0% |
| Jul 2025 | +8.3% |
| Apr 2025 | +7.1% |
| Jan 2025 | -0.9% |
| Oct 2024 | -5.4% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing CSBR
| FY Apr 2026 | n/a |
| FY Apr 2025 | n/a |
| FY Apr 2024 | n/a |
| FY Apr 2023 | n/a |
| FY Apr 2022 | 5.76x |
| Jul 2026 | n/a |
| Apr 2026 | n/a |
| Jan 2026 | n/a |
| Oct 2025 | n/a |
| Jul 2025 | n/a |
| Apr 2025 | n/a |
| Jan 2025 | n/a |
| Oct 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2026-04 | 2025-04 | 2024-04 | 2023-04 | |
|---|---|---|---|---|
| Revenue | $59.4M | $56.9M | $50.2M | $53.9M |
| Operating income | -$1.1M | $4.6M | -$7.4M | -$5.3M |
| Net income | -$1.2K | $4.7K | -$7.3K | -$5.3M |
| EPS (diluted) | -0.08 | 0.33 | -0.54 | -0.39 |
| Operating cash flow | -$4.5M | $7.4M | -$6.1M | $4.0M |
| Cash | $4.9M | $9.8M | $2.6M | $10.1M |
| Buybacks | n/a | $0 | $634.0K | $74.0K |
SEC XBRL, fiscal years, as known on 2026-10-28
CSBR Stock Sonar score 3/7 axes
Find similar shapesCompareCSBR ranks highest on risk and compliance (88th percentile) and growth (52nd), and lowest on institutional and government (14th), among Pharma & Biotech peers.
3 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
